These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

830 related items for PubMed ID: 19157507

  • 1. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R.
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [Abstract] [Full Text] [Related]

  • 2. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
    Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B.
    Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938
    [Abstract] [Full Text] [Related]

  • 3. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R.
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [Abstract] [Full Text] [Related]

  • 4. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [Abstract] [Full Text] [Related]

  • 5. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
    Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, Febbraro A, Colantuoni V.
    Hum Pathol; 2009 May; 40(5):714-25. PubMed ID: 19121846
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B.
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [Abstract] [Full Text] [Related]

  • 7. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma.
    Davidson B, Shih IeM, Wang TL.
    Hum Pathol; 2008 Nov; 39(11):1630-6. PubMed ID: 18656238
    [Abstract] [Full Text] [Related]

  • 8. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R.
    Clin Cancer Res; 2004 Nov 01; 10(21):7335-46. PubMed ID: 15534110
    [Abstract] [Full Text] [Related]

  • 9. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J.
    Hum Pathol; 2011 Jul 01; 42(7):1019-26. PubMed ID: 21315408
    [Abstract] [Full Text] [Related]

  • 10. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B, Baekelandt M, Shih IeM.
    Diagn Cytopathol; 2007 Dec 01; 35(12):756-60. PubMed ID: 18008338
    [Abstract] [Full Text] [Related]

  • 11. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
    Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B.
    Breast Cancer Res Treat; 2005 Nov 01; 94(1):71-80. PubMed ID: 16142438
    [Abstract] [Full Text] [Related]

  • 12. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival.
    Kleinberg L, Holth A, Trope CG, Reich R, Davidson B.
    Hum Pathol; 2008 May 01; 39(5):747-57. PubMed ID: 18439941
    [Abstract] [Full Text] [Related]

  • 13. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
    Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R.
    Gynecol Oncol; 2004 May 01; 93(2):517-23. PubMed ID: 15099972
    [Abstract] [Full Text] [Related]

  • 14. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma.
    Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, Flørenes VA, Davidson B.
    Hum Pathol; 2009 Jun 01; 40(6):795-806. PubMed ID: 19157506
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun 01; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
    Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S.
    Med Sci Monit; 2009 May 01; 15(5):BR148-56. PubMed ID: 19396032
    [Abstract] [Full Text] [Related]

  • 17. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
    Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M, Pilarsky C.
    Clin Cancer Res; 2006 Nov 01; 12(21):6444-51. PubMed ID: 17085658
    [Abstract] [Full Text] [Related]

  • 18. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
    Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R.
    Gynecol Oncol; 2007 Feb 01; 104(2):311-9. PubMed ID: 17030350
    [Abstract] [Full Text] [Related]

  • 19. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
    Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R.
    Clin Cancer Res; 2003 Apr 01; 9(4):1412-9. PubMed ID: 12684413
    [Abstract] [Full Text] [Related]

  • 20. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
    Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM.
    Clin Cancer Res; 2001 Mar 01; 7(3):551-7. PubMed ID: 11297247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.